182 related articles for article (PubMed ID: 12798716)
1. Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
Berkenblit A; Tung N; Kim Y; Feyler H; Niloff J; Berghe KV; Cannistra SA
Gynecol Oncol; 2003 Jun; 89(3):486-93. PubMed ID: 12798716
[TBL] [Abstract][Full Text] [Related]
2. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Look KY; Bookman MA; Schol J; Herzog TJ; Rocereto T; Vinters J;
Gynecol Oncol; 2004 Jan; 92(1):93-100. PubMed ID: 14751144
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Ryan DP; Lynch TJ; Grossbard ML; Seiden MV; Fuchs CS; Grenon N; Baccala P; Berg D; Finkelstein D; Mayer RJ; Clark JW
Cancer; 2000 Jan; 88(1):180-5. PubMed ID: 10618622
[TBL] [Abstract][Full Text] [Related]
4. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; DiSilvestro PA; Waggoner SE; Yamada SD; Armstrong DK; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Dec; 127(3):506-10. PubMed ID: 22943879
[TBL] [Abstract][Full Text] [Related]
5. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
Micha JP; Goldstein BH; Mattison JA; Bader K; Graham C; Rettenmaier MA; Brown JV; Markman M
Gynecol Oncol; 2005 Jan; 96(1):132-5. PubMed ID: 15589591
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.
Hensley ML; Correa DD; Thaler H; Wilton A; Venkatraman E; Sabbatini P; Chi DS; Dupont J; Spriggs D; Aghajanian C
Gynecol Oncol; 2006 Aug; 102(2):270-7. PubMed ID: 16490239
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Spiridonidis CH; Laufman LR; Jones J; Rhodes VA; Wallace K; Nicol S
J Clin Oncol; 1998 Dec; 16(12):3866-73. PubMed ID: 9850032
[TBL] [Abstract][Full Text] [Related]
8. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
9. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Brugnatelli S; Danova M; De Bella MT; Vaglica M; Manuguerra G; Riccardi A; Palmeri S
Oncology; 2002; 62(1):33-8. PubMed ID: 11810041
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
du Bois A; Belau A; Wagner U; Pfisterer J; Schmalfeldt B; Richter B; Staehle A; Jackisch C; Lueck HJ; Schroeder W; Burges A; Olbricht S; Elser G;
Gynecol Oncol; 2005 Feb; 96(2):444-51. PubMed ID: 15661234
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Micha JP; Goldstein BH; Rettenmaier MA; Mattison J; Graham C; Birk CL; Brown JV
Gynecol Oncol; 2004 Sep; 94(3):719-24. PubMed ID: 15350364
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.
Vasey PA; Atkinson R; Coleman R; Crawford M; Cruickshank M; Eggleton P; Fleming D; Graham J; Parkin D; Paul J; Reed NS; Kaye SB
Br J Cancer; 2001 Jan; 84(2):170-8. PubMed ID: 11161372
[TBL] [Abstract][Full Text] [Related]
14. Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
Mäenpää JU; Grénman SE; Jalkanen JT; Kuoppala TA; Leminen AO; Puistola US; Vuolo-Merilä PM; Yliskoski MH
Gynecol Oncol; 2006 Apr; 101(1):114-9. PubMed ID: 16266743
[TBL] [Abstract][Full Text] [Related]
15. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB; Dezube BJ; Faller DV; Dowlati A
Invest New Drugs; 2019 Feb; 37(1):87-97. PubMed ID: 29781056
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
[TBL] [Abstract][Full Text] [Related]
19. SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
Vasey PA; Atkinson R; Osborne R; Parkin D; Symonds R; Paul J; Lewsley L; Coleman R; Reed NS; Kaye S; Rustin GJ
Br J Cancer; 2006 Jan; 94(1):62-8. PubMed ID: 16404361
[TBL] [Abstract][Full Text] [Related]
20. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
